^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Waldenstrom Macroglobulinemia

Related cancers:
2d
Uncovering a lymphoplasmacytic lymphoma/Waldenström macroglobulinemia initially manifesting as dizziness detected through abnormal serum lipemia index: A case report. (PubMed, Medicine (Baltimore))
This case was facilitated by the early detection of discrepancies between lipemia indices and sample appearance despite normal examination results. Additionally, close collaboration between clinical laboratory technicians and clinicians facilitated the uncovering of subtle early disease changes, thereby aiding in precise diagnoses.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
2d
CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations. (PubMed, Histopathology)
Partial positivity for CD23 is a common feature of LPL in the BM. Together with other clinical and histological parameters, CD23 expression supports the differential diagnosis between LPL and MZL.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CXCR4 mutation • MYD88 mutation + CXCR4 mutation
3d
Lymphoplasmacytic lymphoma and Waldenström Macroglobulinemia, A Decade After the Discovery of MYD88L265P. (PubMed, Hum Pathol)
Key concepts in the diagnosis and their clinical implications are emphasized. Controversies and challenges are also discussed.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation • MYD88 L265P
4d
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity. (PubMed, Blood Cancer J)
Collectively, these data suggest that malignant WM B cells actively recruit PMN-MDSCs which promote an immunosuppressive BM microenvironment through a direct T cell inhibition, while release of G-CSF/TNFα in the microenvironment further promotes PMN-MDSC expansion and in turn immune suppression. Targeting PMN-MDSCs may therefore represent a potential therapeutic strategy in patients with WM.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • SDC1 (Syndecan 1)
4d
ROOT: The Registry of Oncology Outcomes Associated with Testing and Treatment (clinicaltrials.gov)
P=N/A, N=167, Completed, Taproot Health | Recruiting --> Completed | N=100000 --> 167 | Trial completion date: Oct 2031 --> Oct 2024 | Trial primary completion date: Oct 2029 --> Oct 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
4d
Enrollment change
|
BGB-16673
5d
Epcoritamab in Previously Treated WM (clinicaltrials.gov)
P2, N=20, Recruiting, Gottfried von Keudell, MD PhD | Not yet recruiting --> Recruiting
Enrollment open
|
Epkinly (epcoritamab-bysp)
5d
GLI3 Is Required for M2 Macrophage Polarization and M2-Mediated Waldenström Macroglobulinemia Growth and Survival. (PubMed, Int J Mol Sci)
In addition, in vitro polarization of M0 macrophages from M-Gli3-/- was not able to induce M2 markers such as CD163, despite inducing iNos expression (M1 marker). Taken together, these results suggest a role for M2 macrophages in promoting WM cell growth and identify GLI3 as a modulator of macrophage polarization.
Journal
|
CD163 (CD163 Molecule) • GLI3 (GLI Family Zinc Finger 3)
|
GLI3 expression
13d
Two Cases of Macroglobulinemia with Elevated Serum CA125: Case Reports and Literature Review. (PubMed, Cancer Manag Res)
At the same time, the clinician could monitor the patient's serum CA125 level changes to assist in the judgment of the efficacy of the original disease. This report extends the understanding of WM and the application of CA125.
Review • Journal
|
MUC16 (Mucin 16, Cell Surface Associated)
|
MUC16 elevation
15d
Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses (ASH 2024)
Uni- and multi-variate analyses of clinical variables that may be associated with clinical and MRD outcomes are underway.Conclusions : Bendamustine, rituximab and acalabrutinib front-line therapy for WM is safe and well tolerated in a relatively elderly population with a toxicity profile consistent with the utilized drugs and not greater than that seen with BR and Placebo in the randomized ECHO trial in untreated Mantle Cell Lymphoma. Initial clinical results show that this treatment is associated with a very high proportion of CR + VGPRs as well as MRD negativity.
Clinical
|
TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
TP53 mutation • MYD88 L265P • CXCR4 mutation
|
clonoSEQ
|
Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine
17d
Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population. (PubMed, Appl Immunohistochem Mol Morphol)
This association will assist in identifying a target population that may benefit from MYD88-specific treatment regimens. This may exponentially improve the outcome of patients with DLBCL harboring this mutation.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation • MYD88 L265P
18d
A Long-term Extension Study of PCI-32765 (Ibrutinib) (clinicaltrials.gov)
P3, N=700, Recruiting, Janssen Research & Development, LLC | Enrolling by invitation --> Recruiting
Enrollment status
|
Imbruvica (ibrutinib)
19d
Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia. (PubMed, Blood Adv)
The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. While further investigation is required, this analysis supports the potential use and further exploration of Bruton tyrosine kinase inhibitors to treat PN symptoms in patients with WM. ClinicalTrials.gov: NCT03053440.
P3 data • Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation
|
Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
21d
New P1 trial
28d
New P1 trial • CAR T-Cell Therapy
1m
LOXO-BCL-20001: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (clinicaltrials.gov)
P1, N=316, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2024 --> Dec 2025
Trial completion date • Metastases
|
Chr t(11;14)
|
Jaypirca (pirtobrutinib) • FCN-338
1m
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry. (PubMed, Hemasphere)
The relative survival (RS) ratio at 5 years of asymptomatic patients was similar to the Spanish population, which contrasted with the 0.76 5-year RS of SWM patients. Overall, the Spanish Multicenter Model comprehensively describes the risk of progression of asymptomatic patients and shows that the excess mortality is increased only in the symptomatic stage of the disease.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • B2M (Beta-2-microglobulin)
|
MYD88 L265P
1m
Twelve-Month Retrospective Evaluation of Clinical Whole-Exome Sequencing (WES) Results for Indolent B Cell Lymphomas (AMP 2024)
Our NGS testing found tier 1 or 2 variants in the majority of cases, supporting its use in the clinical setting. Additionally, a subset of variants identified with the pan-Heme list likely represents mutations of clonal hematopoiesis of indeterminate potential, which could be removed with a more lymphoma-specific gene list. Given these findings, and a growing number of targets in indolent B cell lymphomas, future studies focusing on evaluation of a lymphoma-specific gene list is of interest for clinical validation and implementation.
Retrospective data • Whole exome sequencing
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein)
|
FusionPlex™ Pan-Heme panel • PanHeme assay
2ms
Trial completion date
|
Keytruda (pembrolizumab) • Rituxan (rituximab)
2ms
Characterizing Genomic Variants Defining a Plasma Cell Disorder Patient Cohort Using a Broad Next Generation Multi-Gene DNA Sequencing Panel (ASH 2024)
In our dataset, we have demonstrated several recurrent genomic events which warrant investigation, highlighting the need for further analysis. We will continue to collect data with the aim of further characterizing the complex landscape of all plasma cell disorders.
Clinical
|
TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • NOTCH1 (Notch 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • IL6 (Interleukin 6) • KMT2C (Lysine Methyltransferase 2C) • ARID1B (AT-Rich Interaction Domain 1B)
|
Tempus xT Assay
2ms
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia. (PubMed, Ann Hematol)
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. Moreover, ibrutinib remains an effective treatment after this combination. This study was registered on the clinicaltrial.gov web (NCT02962401, November 9, 2016).
P2 data • Journal
|
TP53 (Tumor protein P53) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
TP53 mutation • CXCR4 mutation
|
Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Zydelig (idelalisib)
2ms
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
2ms
Impact of chromosomal aberrations detected by chromosome banding analysis in symptomatic Waldenström's macroglobulinemia. (PubMed, Ann Hematol)
With a median follow-up of 73 months, the median TTNT in patients with and without CAs was 27 and 68 months, respectively. CAs with CBA may be associated with clinical aggressiveness and shorter TTNT in sWM.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
MYD88 L265P • CXCR4 mutation
2ms
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia (clinicaltrials.gov)
P2, N=46, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026
Trial completion date
|
Rituxan (rituximab) • bortezomib • valacyclovir
2ms
64Cu-LLP2A for Imaging Hematologic Malignancies (clinicaltrials.gov)
P1, N=42, Not yet recruiting, Washington University School of Medicine
New P1 trial
3ms
Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia. (PubMed, Clin Cancer Res)
Testing for MYD88 mutations using AS-PCR or ddPCR in unsorted samples is viable for routine clinical practice. Under BTKi treatment, MYD88 and CXCR4 mutations hold greater prognostic importance than IPSSWM staging in WM.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
MYD88 mutation • CXCR4 mutation • MYD88 mutation + CXCR4 mutation
|
Rituxan (rituximab) • bortezomib
3ms
ARIADNE: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (clinicaltrials.gov)
P=N/A, N=605, Recruiting, iOMEDICO AG | N=400 --> 605 | Trial completion date: Apr 2027 --> Aug 2028 | Trial primary completion date: Apr 2027 --> Aug 2028
Enrollment change • Trial completion date • Trial primary completion date
|
Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
3ms
Journal
|
MME (Membrane Metalloendopeptidase)
3ms
PROFAST Intervention in Precursor Multiple Myeloma (clinicaltrials.gov)
P=N/A, N=40, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2025 --> May 2025 | Trial primary completion date: Jul 2024 --> Jan 2025
Trial completion date • Trial primary completion date
3ms
Paraneoplastic myelitis associated with Waldenström macroglobulinemia responsive to treatment with ibrutinib - venetoclax: A case report. (PubMed, eNeurologicalSci)
Based on radiographic findings, a diagnosis of paraneoplastic LETM was made and he was treated acutely with IV methylprednisolone followed by a quick oral prednisone taper. However, he subsequently relapsed and symptomatically worsened while on rituximab therapy...Our observation of sustained disease response in this patient may support a role for concurrent BTK and BCL2 inhibition in paraneoplastic myelitis associated with B-cell lymphoproliferative disorders. However, this observation needs to be validated in larger cohort studies and potentially in clinical trials if further data are supportive.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 L265P
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • prednisone • methylprednisolone sodium succinate
3ms
NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
|
Imbruvica (ibrutinib) • pevonedistat (MLN4924)
3ms
ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells. (PubMed, Br J Haematol)
We show that pirtobrutinib blocked p-ERK1/2, ERK1/2-driven inflammatory cytokines, and overcame paracrine-mediated resistance in MYD88Mut lymphoma cells expressing mutated BTKCys481. Our results provide important mechanistic insights for the activity of pirtobrutinib in MYD88Mut lymphomas carrying BTKCys481 mutations.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation
|
Imbruvica (ibrutinib) • Jaypirca (pirtobrutinib)
3ms
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (clinicaltrials.gov)
P2, N=22, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2024 --> Jun 2025
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • spanlecortemlocel (MGTA-456)
3ms
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (clinicaltrials.gov)
P1, N=8, Active, not recruiting, Joseph Tuscano | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)
3ms
CLOVER-WaM: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (clinicaltrials.gov)
P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Trial completion date: Jun 2025 --> Dec 2026 | Recruiting --> Active, not recruiting
Enrollment closed • Trial completion date
|
iopofosine I-131 (CLR 131)
3ms
Enrollment change
|
Zydelig (idelalisib)
4ms
Diagnosis and Risk Stratification in Waldenström Macroglobulinemia. (PubMed, J Natl Compr Canc Netw)
The discovery of the recurrent MYD88L265P gain-of-function point mutation and the subclonal CXCR4 mutations has helped improve our understanding of the WM biology, and the prognostic impact of these mutations is under evaluation, with somewhat inconsistent findings thus far across studies. This review discusses the clinical presentation, diagnostic criteria, and prognostic markers of WM.
Review • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
MYD88 L265P • CXCR4 mutation
4ms
MYD88 mutation-positive indolent B-cell lymphoma with CNS involvement: Bing-Neel syndrome mimickers. (PubMed, J Clin Exp Hematop)
These clinical cases emphasize the challenges in diagnosing BNS. Based on the findings, biopsy is recommended for accurate identification of the clonal relationship and MYD88 mutation status.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IGH (Immunoglobulin Heavy Locus)
4ms
From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation. (PubMed, Ann Diagn Pathol)
In conclusion, composite lymphoma can present in the bone marrow. The use of ancillary studies was essential in reaching the diagnosis in this case, as the results excluded the possibility of MCL lymphoma with plasmacytic differentiation, as well as other CD5- and CD10-negative small B-cell lymphomas.
Review • Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CCND1 (Cyclin D1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
4ms
ZBR: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (clinicaltrials.gov)
P2, N=42, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | N=30 --> 42
Enrollment change
|
Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
4ms
Phase classification • Combination therapy
|
Imbruvica (ibrutinib) • Xolremdi (mavorixafor)
4ms
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. (PubMed, Br J Haematol)
Treatment was well tolerated, with minimal numbers of immune-mediated AEs typically seen with checkpoint inhibitors. PembroWM is the first study to evaluate the feasibility of PD-1 axis modulation in WM and has shown that in combination with Rituximab the combination is safe and deliverable.
P2 data • Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
Keytruda (pembrolizumab) • Rituxan (rituximab)